Sovaldi
Formulated for chronic hepatitis c to mitigate viral progression.
- Category
- Antivirals
- Active ingredient
- Sofosbuvir
- Supply
- Pharmacy
- Route
- Oral use
- Form
- Film-coated tablet
- Strengths
- 400mg
Sovaldi details
- Condition
- Chronic Hepatitis C
- Alternative names
- MyHep
- Therapeutic class
- Hepatitis C Antiviral
- Pharmacological class
- NS5B Polymerase Inhibitor
- Contraindications
- hypersensitivity to sofosbuvir
- Minor side effects
- fatigue; headache
- Moderate side effects
- nausea; insomnia
- Serious side effects
- hypersensitivity, requires immediate medical attention
- Dosage forms
- Film-coated tablet
- Administration route
- Oral use
- Patient summary
- Formulated for chronic hepatitis c to mitigate viral progression.
- Supply category
- Pharmacist only, dispensed without a prescription
- Manufacturer
- Gilead Sciences
- Onset Time
- 1–2 weeks
- Duration
- 12–24 weeks
- Storage instructions
- Store below 30°C in the original container.
- Drug interactions
- amiodarone; rifampicin
- Age restrictions
- For adult use.
Mechanism of action
An NS5B polymerase inhibitor that blocks the replication machinery of the hepatitis C virus, thereby reducing viral load.
Pregnancy and breastfeeding
Pregnancy: Consult a healthcare professional before use. Breastfeeding: Breastfeeding is not recommended during therapy.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Sovaldi
Sovaldi is the original Gilead Sciences brand of sofosbuvir, a treatment used for chronic hepatitis C. The same active ingredient is also sold as Myhep, supplied as a 400mg tablet. This antiviral medication functions by inhibiting the replication of the virus within the body.
Sovaldi availability in Asia
Sovaldi is registered across 14 markets including Singapore, Hong Kong and Thailand, with availability also in Malaysia, the Philippines and Indonesia. Generic sofosbuvir, much of it made in India, is often more affordable than the original brand, offering important access for patients located far from a well stocked supply source. These treatments are best used under a doctor’s care to monitor the condition, regardless of the user’s location across the region.